^
Association details:
| Biomarker: | CBL mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Myelodysplastic…Subtype...CMML-2…Frequent mutations...TET2, SRSF2, ASXl1, RUNX1, NRAS, CBL…HMA ± ruxolitinib…
